The study of the efficacy of the Transdiagnostic Treatment of the Unified for the Improvement of Comorbid Psychological Disorders in Ms Patients

Not Applicable

Recruiting

• Conditions: comorbidity of Psychological disorders in Patient with MS.; Other specified mental disorders due to brain damage and dysfunction and to physical disease; F06.8

• Registration Number: IRCT20180421039369N2
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 May 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

Suffering Ms disease with diagnosis of the neurological department
Having a score of less than 5 in the (EDSS) Disability Indicator based on a neurologist's assessment to determine the individual's ability to attend a therapeutic session
The age range is between 50 to 18 years old
Affliction of emotional coexistence disorders including depression, anxiety and health anxiety based on diagnostic interview by psychologist
Motivation and satisfaction for participation during treatment and research implementation
Failure to receive psychological treatment in the past year
Have at least a cycle of educationNot having other chronic diseases such as severe liver disorder
The lack of current diagnosis of any mental disorder is consistent in Diagram 1 and 2 based on a psychologist's diagnostic interview, with the exception of emotional disorders including depression, anxiety and health anxiety
No obvious risk of suicide now
There is no history of drug abuse or dependence at the current time and within one year before the start of treatment

Exclusion Criteria

Unwillingness to attend research meetings
Not attending at least 50% of the sessions
Creating severe physical problems so that it can not be present at meetings

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Comorbidity of psychological disorders of patients with MS. Timepoint: A week before the intervention, one week after the intervention, Three months after the intervention. Method of measurement: Beck Depression Inventory (BDI-II), Beck Anxiety Inventory, Short form Health Anxiety Scale (SHIA), Fatigue Exercise Scale (FSS), and Quality of Life Scale (MSQOL-54) questionnaire.

Secondary Outcome Measures

Name	Time	Method
Depression. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Beck Depression Inventory (BDI-II).;Anxiety. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Beck Anxiety Inventory.;Health Anxiety. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Short Form Health Anxiety Scale (SHIA).;Fatigue Severity. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Fatigue Severity Scale (FSS).;Quality of Life. Timepoint: A week before the intervention, one week after the intervention, three months after the intervention. Method of measurement: Multiple Sclerosis Quality of Life-54 (MSQOL-54).